Pennsylvania Trust Co Lowers stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Pennsylvania Trust Co reduced its stake in Abbott Laboratories by 1.44% during the most recent quarter end. The investment management company now holds a total of 223,463 shares of Abbott Laboratories which is valued at $9,115,056 after selling 3,256 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Oct 14, 2016.Abbott Laboratories makes up approximately 0.75% of Pennsylvania Trust Co’s portfolio.

Other Hedge Funds, Including , Forte Capital Adv reduced its stake in ABT by selling 500 shares or 7.29% in the most recent quarter. The Hedge Fund company now holds 6,363 shares of ABT which is valued at $260,756. Abbott Laboratories makes up approx 0.10% of Forte Capital Adv’s portfolio.Osborn Rohs Williams Donohoe Ltd reduced its stake in ABT by selling 6,201 shares or 4.34% in the most recent quarter. The Hedge Fund company now holds 136,702 shares of ABT which is valued at $5,626,654. Abbott Laboratories makes up approx 1.10% of Osborn Rohs Williams Donohoe Ltd’s portfolio.Genesee Valley Trust Co reduced its stake in ABT by selling 2,559 shares or 10.6% in the most recent quarter. The Hedge Fund company now holds 21,593 shares of ABT which is valued at $888,768. Abbott Laboratories makes up approx 0.57% of Genesee Valley Trust Co’s portfolio. Hilton Capital Management added ABT to its portfolio by purchasing 22,165 company shares during the most recent quarter which is valued at $964,178. Abbott Laboratories makes up approx 0.25% of Hilton Capital Management’s portfolio.

Abbott Laboratories closed down -0.19 points or -0.46% at $40.79 with 88,18,965 shares getting traded on Friday. Post opening the session at $41.17, the shares hit an intraday low of $40.77 and an intraday high of $41.53 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.